Bblueprint
Freenome applies machine learning to blood-based cancer screening
Understand Freenome’s AI screening platform, SimpleScreen CRC approval, test limitations and the distinction between approval and commercial access.
Models & infrastructureTue, 22 Sept 2026
8 minread


